Tag: SGLT2 inhibitors
Blood test may predict heart, kidney risk for those with type...
A simple blood test may predict the risk of progressive kidney and heart disease in people with type 2 diabetes and kidney disease, according to new...
Empagliflozin approved in the EU for CKD
The European Commission (EC) has approved Jardiance (empagliflozin) for the treatment of adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company has...
UK Kidney Week preview: SGLT2i guideline update builds on new evidence
Andrew Frankel, consultant physician and nephrologist at Imperial College Healthcare NHS Trust (London, UK), writes to set out the process behind the new guideline...
KDIGO guideline for diabetic CKD patient treatment updated
The Kidney Disease: Improving Global Outcomes (KDIGO) Work Group has issued a 2022 update to its 2020 guideline for the management of diabetes in...
SGLT2 inhibitors demonstrate efficacy and safety in diabetic kidney transplant recipients
Sodium-glucose cotransporter-2 (SGLT2) inhibitors can be used safely to help preserve graft function in diabetic kidney transplant recipients, as per the findings from a...